(Q33852973)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10699310%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

review article

1 reference

title

Tuftsin-bearing liposomes in treatment of macrophage-based infections (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10699310%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10699310%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

author name string

Agrawal AK

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10699310%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

language of work or name

English

0 references

publication date

1 March 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10699310%20AND%20SRC:MED&resulttype=core&format=json

Advanced Drug Delivery Reviews

4 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10699310%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

volume

41

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10699310%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10699310%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

page(s)

135-146

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10699310%20AND%20SRC:MED&resulttype=core&format=json

Multiple emulsions as targetable delivery systems

4 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Drug delivery systems. 6. Transdermal drug delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Engineering liposomes for drug delivery: progress and problems

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Polyethylene glycol modification: relevance of improved methodology to tumour targeting

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Liposomes as drug carriers in leishmaniasis and malaria.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Liposomes in the treatment of infections

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Specific interactions of liposomes with PMN leukocytes upon incorporating tuftsin in their bilayers

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Protection of mice against Plasmodium berghei infection by a tuftsin derivative.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Interactions of tuftsin with bovine serum albumin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Drug targeting in Leishmania donovani infections using tuftsin-bearing liposomes as drug vehicles

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Respiratory burst in peritoneal exudate cells in response to a modified tuftsin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Tuftsin-bearing liposomes as drug vehicles in the treatment of experimental aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Tuftsin-bearing liposomes as rifampin vehicles in treatment of tuberculosis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Tuftsin: its chemistry, biology, and clinical potential

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Prophylaxis of Candida albicans infection with tuftsin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Construction of a synthetic immunogen: use of the natural immunomodulator polytuftsin in malaria vaccines against RESA antigen of Plasmodium falciparum.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Isolation and subunit composition of tuftsin receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Enhanced phagocytosis activity of cyclic analogs of tuftsin.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

1-Aminocyclobutanecarboxylic acid derivatives as novel structural elements in bioactive peptides: application to tuftsin analogs

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Tuftsin, Thr-Lys-Pro-Arg. Anatomy of an immunologically active peptide

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Tuftsin analogs for probing its specific receptor site on phagocytic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Preferred conformation and molecular packing of phosphatidylethanolamine and phosphatidylcholine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Time to put malaria control on the global agenda.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Surveillance of antifolate-resistant malaria.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Drug resistance in malaria parasites of animals and man.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Chloroquine-resistant Plasmodium falciparum and the MDR phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Malaria: dissecting chloroquine resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Chloroquine blood levels after administration of the liposome-encapsulated drug in relation to therapy of murine malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Growth inhibition of Plasmodium falciparum in in vitro cultures by selective action of tryptophan-N-formylated gramicidin incorporated in lipid vesicles.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Plasmodium vinckei: optimization of desferrioxamine B delivery in the treatment of murine malaria

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Liposomal vaccines: clinical status and immunological presentation for humoral and cellular immunity.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Immunization against the murine malaria parasite Plasmodium yoelii using a recombinant protein with adjuvants developed for clinical use.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Antibody-mediated targeting of liposomes to erythrocytes in whole blood

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Antibody-mediated targeting of liposomes to red cells in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Functional drug targeting to erythrocytes in vivo using antibody bearing liposomes as drug vehicles

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Chloroquine encapsulated in malaria-infected erythrocyte-specific antibody-bearing liposomes effectively controls chloroquine-resistant Plasmodium berghei infections in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Visceral leishmaniasis: drug carrier system characteristics and the ability to clear parasites from the liver, spleen and bone marrow in Leishmania donovani infected BALB/c mice

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Mannose-coated liposomal hamycin in the treatment of experimental leishmaniasis in hamsters

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Drug delivery system: targeting of pentamidines to specific sites using sugar grafted liposomes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Antifungal drugs on the horizon

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Entry of five antifungal agents into the ovine lung

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Liposomal amphotericin B in neonates with invasive candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Antifungal agents. Part I. Amphotericin B preparations and flucytosine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Disposition of aerosolized liposomal amphotericin B.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Study of the effects of liposomal amphotericin B on Candida albicans, Cryptococcus neoformans, and erythrocytes by using small unilamellar vesicles prepared from saturated phospholipids

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Affinity of amphotericin B for phosphatidylcholine vesicles as a determinant of the in vitro cellular toxicity of liposomal preparations

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

On the track of "killer" TB.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Side-effects of drug regimens used in short-course chemotherapy for pulmonary tuberculosis. A controlled clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

New antibacterial drugs for the treatment of mycobacterial disease in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Use of liposome preparation to treat mycobacterial infections

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

In vivo induction of apoptosis in the thymus by administration of mycobacterial cord factor (trehalose 6,6'-dimycolate)

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021

Distribution of liposomes in tuberculous mice

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900061-7

7 January 2021